These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37605506)

  • 1. Lipid-Polymer Hybrid Nanoparticles with Both PD-L1 Knockdown and Mild Photothermal Effect for Tumor Photothermal Immunotherapy.
    Chuan D; Fan R; Chen B; Ren Y; Mu M; Chen H; Zou B; Dong H; Tong A; Guo G
    ACS Appl Mater Interfaces; 2023 Sep; 15(36):42209-42226. PubMed ID: 37605506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
    Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
    Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
    Teo PY; Yang C; Whilding LM; Parente-Pereira AC; Maher J; George AJ; Hedrick JL; Yang YY; Ghaem-Maghami S
    Adv Healthc Mater; 2015 Jun; 4(8):1180-9. PubMed ID: 25866054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatiotemporal-Controlled NIR-II Immune Agonist Sensitizes Cancer Immunotherapy.
    Guo S; Tang D; Zhang M; Yang H; Zhang T; Hu B; Xu C; Weng Y; Shang K; Huang Y
    Adv Mater; 2024 Jun; 36(25):e2400228. PubMed ID: 38477852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy.
    Tang Y; Chang Q; Chen G; Zhao X; Huang G; Wang T; Jia C; Lu L; Jin T; Yang S; Cao L; Zhang X
    Biomater Adv; 2023 Jul; 150():213425. PubMed ID: 37084635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
    Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
    J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal immunotherapy for triple-negative breast cancer under near-infrared laser irradiation.
    Wang Y; Wang H; Song Y; Lv M; Mao Y; Song H; Wang Y; Nie G; Liu X; Cui J; Zou X
    J Nanobiotechnology; 2022 Mar; 20(1):96. PubMed ID: 35236356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy.
    Jia D; Zhao S; Liu H; Zhan X; Zhou Z; Lv M; Tang X; Guo W; Li H; Sun L; Zhong Y; Tian B; Yuan D; Tang X; Fan Q
    Int J Biol Macromol; 2024 Jun; 269(Pt 2):132058. PubMed ID: 38704065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
    Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
    Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision USPIO-PEG-SLe
    Li T; Guo L; Li J; Mu X; Liu L; Song S; Luo N; Zhang Q; Zheng B; Jin G
    Int J Nanomedicine; 2024; 19():1249-1272. PubMed ID: 38348177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-immunizing with PD-L1 induces CD8
    Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
    Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
    Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectively down-regulated PD-L1 by albumin-phenformin nanoparticles mediated mitochondrial dysfunction to stimulate tumor-specific immunological response for enhanced mild-temperature photothermal efficacy.
    Zhou Z; Jiang N; Chen J; Zheng C; Guo Y; Ye R; Qi R; Shen J
    J Nanobiotechnology; 2021 Nov; 19(1):375. PubMed ID: 34794446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.